Your trusted source for investing success

Tag: cancer

Looking for Cannabis Stocks?

Read our report to find market data, important news and stocks to watch!
 

Moleculin Announces Pricing of $9 Million Registered Direct Offering

Moleculin Biotech (NASDAQ: MBRX) a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center, announced that it has entered into a definitive agreement with institutional investors

Affimed Announces Closing of Public Offering of Common Stock and Exercise of Underwriters’ Option to Purchase Additional Shares

Affimed (Nasdaq:AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced the closing of its previously announced public offering of 13,225,000 of its common shares at a public offering price of $2.00 per common share.

As quoted in the press release:

The total includes 1,725,000

JAMA Oncology Publication Demonstrates EndoPredict Significantly Outperforms Oncotype DX

Myriad Genetics (NASDAQ:MYGN) today announced that a comparative analysis of commercially available prognostic breast cancer tests in patients with early-stage breast cancer has been published in JAMA Oncology.  A key finding is that Myriad’s EndoPredict® (EPClin) significantly outperformed Oncotype DX® Recurrence Score at predicting the risk of disease recurrence in patients with early-stage

Genocea Reports Fourth Quarter and Full-Year 2017 Financial Results

Genocea Biosciences (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2017 and recent corporate developments.

As quoted in the press release:
“We’ve had a productive start to 2018 and are encouraged by both the progress with our lead neoantigen

Asterias Expands Global IP Portfolio with New Patents

Asterias Biotherapeutics (NYSE:AST), a biotechnology company dedicated to developing regenerative medicine therapeutics to treat neurological conditions associated with de-myelination and cellular immunotherapies to treat cancer, today announced that it has strengthened its global IP portfolio over the past 12 months with the issuance of 46 new patents, including in the

Genetic Technologies Announces Strategic Alliance and Capital Raising

Genetic Technologies (NASDAQ:GENE) a molecular diagnostics company and provider of BREVAGenplus®, a first-in-class, clinically validated risk assessment test for sporadic (non-hereditary) breast cancer, is pleased to announce that it has entered into a non-binding terms sheet with Blockchain Global Limited ACN 601 628 497.

As quoted in the press release:
Dr Paul

Motus Goes Public on the NASDAQ

Motus Goes Public on the NASDAQ

Medical device company, Motus (NASDAQ:MOTS), made the switch from private to public today on the NASDAQ Capital market, but Renaissance Capital stated the company’s initial public offering (IPO) on the low side of $5 instead of a high of $7.

Agios Reports Fourth Quarter and Full Year 2017 Financial Results

Agios Pharmaceuticals (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2017. In addition, Agios highlighted select 2018 corporate milestones and data presentations for its clinical development

Pieris Pharmaceuticals Announces Public Offering of Common Stock

Pieris Pharmaceuticals (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for cancer, respiratory and other diseases, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. Pieris intends to grant the underwriters a 30-day option to

Affimed Announces Proposed Public Offering of Common Stock

Affimed (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced that it has commenced an underwritten public offering of its common shares. The company expects to grant the underwriters a 30-day option to purchase up to an additional 15 percent of

Avid Bioservices and Oncologie Enter Into Asset Assignment and Purchase Agreement

Avid Bioservices (NASDAQ:CDMO) and Oncologie, Inc. today announced that the companies have entered into an Asset Assignment and Purchase Agreement for Avid’s phosphatidylserine (PS)-targeting program including bavituximab.

As quoted in the press release:
“Partnering our PS-targeting program including bavituximab with a biopharmaceutical company focused on therapeutics in oncology has long been a

Enter Your Log In Credentials
This setting should only be used on your home or work computer.

×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network

Send this to a friend

Hi,
I thought you might find this interesting:
Cannabis Weekly Round-Up: Two Provinces Reveal Deals in Place for Recreational Market

URL: https://investingnews.com/daily/resource-investing/agriculture-investing/cannabis-investing/cannabis-weekly-roundup/